Slides
Page 1
Financial Year 2025 Results Annual Conference 12 February 2026
Page 2
2 Today’s Agenda Full-Year 2025 Financial Review Judith van Walsum, PhD, CFO 2026 Market Expectations and Outlook Volker Cwielong, CEO Questions & Answers Highlights and Business Review 2025 Volker Cwielong, CEO1 2 3 4
Page 3
Highlights and Business Review 2025 3
Page 4
Datwyler Accelerates with Healthcare-Driven Growth and Stronger Profitability 4 Net revenues of CHF 1,100.5m, delivering +3.1% currency-adjusted growth, with FX headwinds of -3.7% EBIT margin increased to 12.4% (+1.7pp YoY , adjusted for transformation costs), driven by Healthcare scale effects, improved product mix, and initial benefits from ForwardNow Healthcare division confirmed as core growth engine, with +8.1% currency- adjusted growth, successful GLP-1 production ramp-up, increasing NeoFlex traction, and continued HVO expansion (~70% of project pipeline) Industrial division resilient with stable currency-adjusted revenues and profitability improved to 8.9% (+0.4 pp YoY), supported by growth in Food & Beverage and Automotive applications in Asia ForwardNow transformation on track, with early efficiency gains visible and supporting delivery of the program’s financial targets
Page 5
Advancing Profitable Growth in a Dynamic Environment Through Focused Execution 5 Datwyler Division Healthcare Datwyler Division Industrial * Revenue share in 2025 42%* 27%* 11%*20%* Healthcare Structural growth supported by normalized ordering patterns, strong customer demand and new product launches Automotive Selective growth driven by China and platform-specific applications, despite slower BEV ramp-up Industries Focused portfolio serving attractive niches with disciplined execution Food & Beverage Stable growth profile supported by the regulatory- driven shift from plastic to aluminum
Page 6
Full-Year 2025 Financial Review 6
Page 7
Currency Headwinds Offset Growth but Profitability Significantly Increased Reported revenue –0.6%; currency- adjusted +3.1%, driven by Healthcare. Gross margin increased to 23.4% (PY 21.5%) due to higher share of High-Value products in Healthcare, efficiency gains and cost saving measures. Lower Operating Expenses, as PY contained CHF 37.9M ForwardNow costs. EBIT reached CHF 136.6M (PY adjusted for ForwardNow at CHF 118.1M). EBIT margin improvement from 10.7% (PY adjusted) to 12.4%. Net result above adjusted PY (CHF 69.0m), supported by lower debt and hedging costs despite higher taxes. 7 Profit and Loss Statement in CHF M 1 2 3 6 4 1 2 3 4 5 in CHF M FY2025 ACT Net revenue 1’100.5 Costs of goods sold (842.6) FY2024 ACT Δ in % 1’107.7 -0.6% (869.4) -3.1% Gross profit 257.9 238.3 8.2% Operating Expenses (121.3) (158.1) -23.3% EBIT 136.6 80.2 70.3% Net finance result (23.2) (27.9) -16.8% Earnings before tax (EBT) 113.4 52.3 116.8% Income tax expenses (32.6) (21.2) 53.8% Net result 80.8 31.1 159.8% in % of net revenue Δ in pp Gross profit margin 23.4% 21.5% 1.9pp EBIT-margin 12.4% 7.2% 5.2pp in CHF Δ in % Net result per bearer share 4.75 1.83 159.6%
Page 8
Reported Revenue Impacted by FX Headwinds; Underlying Growth Driven by Healthcare ◆ Top line impacted by CHF -41.2m FX (-3.7%) due to strong CHF. ◆ Currency-adjusted growth at +3.1% reflects strong growth in Healthcare partly offset by weaker Automotive demand. ◆ Price adjustments and higher volume, notably driven by Healthcare, largely offset FX headwinds. 8 Revenue FY 2024 (41.2) Foreign currency / IC eliminations GPI Price Changes CY/PY Sales to 3rd Volume Revenue FY 2025 1’107.7 1’100.5 9.8 24.2 Revenue Bridge Full Year 2025 in CHF M
Page 9
EBIT Strongly Above PY on Mix, Efficiency and ForwardNow Execution ◆ Operational impact of slightly lower revenues more than offset by mix, pricing, volume and efficiency gains. ◆ Of CHF 37.9m ForwardNow costs in PY, CHF 9.4m impairments and CHF 28.5m provisions; CHF 4.7m used in 2025, remainder in 2026-27. ◆ EBIT margin of 12.4% clearly above PY adjusted 10.7% and reported 7.2%. 9 EBIT FY 2024 -4.3 Foreign Currency Net Revenue -5.4 COGS -5.8 Net other OpEx (1) GTP 2024 EBIT FY 2025 80.2 136.6 34.0 37.9 EBIT Bridge Full Year 2025 in CHF M Notes: GTP = Group Transformation Program; LfL = Like for Like comparison. (1) Net other Operating Expenses includes Research and Development (R&D), Marketing and Selling (M&S) and General and Adminis trative (G&A).
Page 10
Healthcare Growth Accelerates in HY2 Driven by High Value Offering ◆ Reported revenue with significant currency headwinds 3.7% above PY, currency adjusted growth at 8.1%. ◆ H1 still impacted by destocking; strong H2 driven by favourable product mix due to ramp-up of new high-value projects, with strong EBIT fall-through. ◆ EBIT margin rose to 17.1% (PY adj. 13.9%) on improved utilization and mix-driven gross margin expansion. 10 56% Europe24% Americas 19% Asia 1% Other Revenue split by regions 2025 in % FY 2024 FY 2025 446.0 462.7 +3.7% Revenue in CHF M EBIT in CHF M (2024 adjusted) / EBIT margin in % (2024 adjusted) 13.9% FY 2024 17.1% FY 2025 61.8 79.3 +28.3% 35% HVO 65% Non-HVO Revenue split by product category 2025 in %
Page 11
Industrial Solutions Improved EBIT Despite a Flat, Currency-Adjusted Top Line ◆ Revenues with FX headwind -3.3% below PY, FX adjusted flat (0.0%). Unfavourable FX impact of CHF -22.1M. ◆ Automotive remained challenging; General Industry grew from low base; Food & Beverage stable. ◆ EBIT margin improved from 8.5% (PY adj.) to 8.9% on cost measures, operational improvements and Property, Plant & Equipment gains. 11 -10.6% (-8.0%)1 50% Europe 28% Americas 21% Asia 1% Other Revenue by destination in % FY 2024 FY 2025 664.8 642.8 -3,3% Revenue in CHF M EBIT in CHF M (2024 adjusted) / EBIT margin in % (2024 adjusted) 8,5% FY 2024 8,9% FY 2025 56.3 57.3 +1,8% 47% Automotive 35% Food & Beverage 19% Industries Revenue split by end-markets 2025 in %
Page 12
Strong Momentum in H2 2025 Supports Improved EBIT Performance ◆ H2 margin uplift driven by increased demand for High Value Offering products in Healthcare. ◆ Industrial improved in H2 through structural cost measures and tailwind from sale of Property, Plant & Equipment. 12 EBIT in CHF M (2024 adjusted) / EBIT margin in % (2024 adjusted) Group Healthcare Industrial 11.8% H1 2024 9.5% H2 2024 12.2% H1 2025 12.6% H2 2025 67.5 50.6 68.9 67.7 15.4% H1 2024 12.2% H2 2024 16.9% H1 2025 17.4% H2 2025 35.6 26.2 40.1 39.2 9.3% H1 2024 7.6% H2 2024 8.7% H1 2025 9.1% H2 2025 31.9 24.4 28.8 28.5
Page 13
Net Financial Result Lower, Effective Tax Rate Back to Expectations Improving Net Result ◆ Net interest improved by CHF 0.9m following debt repayments. ◆ Hedging costs improved by CHF 3.8m vs PY. ◆ Higher taxable income led to a higher nominal tax expense. The effective tax rate decreased to 28.7% (PY 40.5%); the weighted average tax rate was 23.6%, with non-recoverable withholding taxes and selected non-recognized DTAs increasing the rate to 28.7%. 13 Income tax expense in CHF M FY 2022 FY 2023 FY 2024 FY 2025 12.3 28.7 27.9 23.2 FY 2022 FY 2023 FY 2024 FY 2025 32.1 24.9 21.2 32.6 Total interest and finance expenses in CHF M
Page 14
Net Working Capital with Notable Improvements in Trade Accounts Payables ◆ Net working capital overall with a notable step forward towards our mid-term target of better cash conversion. ◆ Trade Accounts Receivables stayed flat with strong sales in second half of 2025. ◆ Trade Accounts Payables with the most significant progress thanks to strengthened procurement. • Inventory improved, reflecting higher sales growth and better inventory management; safety stock levels influenced by geopolitical volatility. 14 216 216 169 160 -73 -81 FY 2024 FY 2025 311 295 Net Working Capital in CHF M Inventories Trade Accounts Receivable Trade Accounts Payable
Page 15
Deleveraging Continued with Improved Net Debt to LTM EBITDA Ratio ◆ All bank debt repaid during 2024. ◆ Net debt consisting of ◆ 1.70% CHF 120M bond placed in April 2024 (repayable in 2029) ◆ 2.10% CHF 240M bond placed in 2022 (repayable in 2027) ◆ Pema loan CHF 145.0M (CHF 70M repaid in 2025) ◆ Cash balance (deducted) CHF 125.3M. ◆ Net debt / EBITDA ratio further improved as EBITDA increased and net debt went down. 15 Net Debt in CHF M and net debt / EBITDA as Ratio -129 596 517 447 379 -200 -100 0 100 200 300 400 500 600 700 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 3.0 in CHF M Ratio net debt / EBITDA -0.4 2021 2022 2023 2024 2025 2.6 2.6 2.2 1.8 Net debt / EBITDA (2021 and 2024 adjusted) Net debt (+) / Net cash surplus (-) per year-end
Page 16
Free Cash Flow Remained Strong in Absolute Terms, Enabler for Continued Debt Reduction ◆ Operating cash flow up 1.2% vs. PY. The 2024 baseline reflected ForwardNow provision corrections and impairments; in 2025, higher revenues increased TAR, partly offset by improved TAP. ◆ Capex CHF 7.9M higher than in PY, offset by cash collections from PP&E sales of CHF 7.7M, including two real estate sales in the US due to site closure and pending site consolidation. ◆ Free cash flow at CHF 129.4m, used for further debt reduction. 16 Free Cash Flow in CHF M FY2025 ACT Net cash from operating activities 173.8 Net cash used in investing activities (44.4) FY2024 ACT Free cash flow (FCF) 129.4 Net cash used by financing activities (126.1) Dividend proposal CHF 3.20 per bearer share 171.7 (43.8) 127.9 (124.9)
Page 17
2026 Market Expectations and Outlook 17
Page 18
Confident Outlook for Continued Earnings and Value Creation Through Execution-Driven Growth 18 Market Expectations 2026 Datwyler Positioning Healthcare Automotive Food & Beverage Industries ◆ Structural growth in injectables, biologics and self-administration therapies continues ◆ GLP-1 momentum and scalable primary packaging demand remain strong ◆ Global vehicle production broadly flat ◆ BEV growth structurally intact despite short- term volatility ◆ Sustained growth momentum in aluminum- compatible capsules (3–5% CAGR) ◆ Regulatory developments reinforcing the long- term shift toward aluminum solutions ◆ Stable demand with selective growth in structurally attractive target markets ◆ Energy, Aerospace & Defense show structurally stronger momentum ◆ Portfolio shift toward higher-margin niches with durable entry barriers and concentrated presence in energy, aerospace, defense and medical technology applications ◆ Targeted exposure to compatible aluminum capsules in attractive, low-cyclical segment ◆ Capsul’in expands scale and IP, with capacity doubling from early 2025 to mid-2026 ◆ Well-positioned with Chinese OEMs and platform-specific applications in electrification- related systems ◆ Strong focus on high-value injectables and GLP-1 ramp-ups, supported by NeoFlex ◆ HVO share increasing in revenues, enabling scalable growth with high operating leverage
Page 19
Outlook 2026: Advancing Datwyler’s Performance through Consistent Execution 19 ◆ Ongoing optimization of the global production and technology footprint improves cost efficiency, standardization, capital allocation and speed to industrialization ◆ Continue to enhance earnings quality and streamline complexity through disciplined portfolio management focused on high-value, system-critical components ◆ Further strengthen commercial excellence and value-based pricing to improve project selectivity and conversion of growth into earnings ◆ Consistent execution of ForwardNow delivers measurable efficiency gains and structurally higher margins, supporting progress toward mid-term profitability targets Product Portfolio Optimized Footprint Commercial Excellence Innovation to launch Execution Discipline Organizational Focus 2026 ◆ Prioritize speed in bringing our innovations from implementation to commercialization in Healthcare and Industrial and our Venture Units
Page 20
Clear Strategic Focus: Value Creation from Early-Stage Design to High-Volume Production 20 ◆ Market leadership secured through unique competencies ◆ Optimized solutions from early collaboration ◆ End-to-end integration from design to production ◆ Global reach, local expertise and manufacturing ◆ Synergies across the markets that drive competitive advantage
Page 21
21 Disciplined Capital Allocation Balancing Profitability, Cyclicality and Investment Intensity ◆ Based on our current market positions, we will ensure that our future organic growth will lead to a more profitable and less cyclical and investment intensive business portfolio. ◆ Our capital allocation follows a disciplined approach to sustainably implement our growth and margin targets and increase Datwyler's competitiveness and resilience. ◆ In a longterm view, selective inorganic growth will be a strategic lever to grow in low cyclical and high margin markets. Cyclicality LOW HIGH Shape size: % of EBIT contribution to the group CAPEX IntensityLOW HIGH Healthcare Industrial
Page 22
Capsul’in Acquisition Strengthens Datwyler’s Solution Design Capabilities and Completes the Business Model 22 Structurally growing, low-cyclical market for compatible aluminum capsules, supported by high technical, quality and regulatory entry barriers Compelling combination of strengths:Datwyler’s material expertise and industrialization capabilities paired with Capsul’in’s solution design and innovation leadership Regulation-driven shift from plastic to aluminum accelerating growth in the Aluminum Compatible Market (3–5% CAGR) Mid double-digit CHF revenue contribution upon consolidation (FY 2026 onwards) High-Volume Automated Manufacturing Meets Continuous Improvement Discipline Collaborative Design Expertise with Forward- Looking Capability Expansion Material Leadership Powering High-Performance Aluminum and Silicone Bonding
Page 23
23 Mid-Term Targets Under Normal Operating Market Conditions Revenue CAGR (organic) Higher single digit EBIT-margin 17% plus GROUP HEALTHCARE DIVISION INDUSTRIAL DIVISION Revenue CAGR ~8% EBIT-margin ~22% Revenue CAGR ~4% EBIT-margin ~12%
Page 24
Orderly Succession in the Board of Directors Ensuring Continuity and Strategic Oversight 24 Dr. Gabi Huber Jürg Fedier Stephanie Bregy Christian Holzgang
Page 25
Planned Change to the Datwyler Chair of the Board due to Age-Related Resignation at the Ordinary General Meeting 2027 25 Paul Hälg Chairman since 2017 CEO from 2004 to 2026 Jens Breu (1972, CH) Director since 2019 CEO of SFS Group
Page 26
Questions & Answers 26
Page 27
27 Financial Calendar 2026 Company events 13 February 16 February 3 March 5 March 17 March 23 July September Investor conferences 12 May 8-10 June 23-24 September 4-6 November Roadshow Zurich Roadshow Frankfurt Roadshow Geneva Roadshow London Annual General Meeting, Altdorf Half year results presentation Roadshow Zurich, Frankfurt, Geneva & London Kepler Cheuvreux, Zurich Commerzbank and ODDO BHF, Interlaken UBS, Wolfsberg ZKB, Zurich
Page 28
28 This presentation contains forward-looking statements that reflect the Group’s current expectations regarding market conditions and future events and are therefore subject to a number of risks, uncertainties and assumptions. Unanticipated events could cause actual results to differ from those predicted and from the information contained in this presentation. All forward-looking statements in this presentation are qualified in their entirety by the foregoing. Datwyler Holding Inc. Gotthardstrasse 31, 6460 Altdorf T +41 41 875 11 00 F +41 41 875 12 05 info@datwyler.com , www.datwyler.com Disclaimer